BioSpace News Archive

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced positive topline results from the AURORA 2 continuation study evaluating the long-term safety and tolerability of LUPKYNIS™.

Johnson & Johnson announced the appointment of several senior leaders to the Company’s Executive Committee.

Exai Bio Secures $67.5 Million Series A Financing to Advance Next-Generation, RNA-Based Liquid Biopsy Platform for Early Cancer Detection.

Acquisition complements BD’s core portfolio - adding an innovative, broadly applicable surgical sealant to a suite of BD biosurgery products already relied upon in the operating room.

TYME Technologies, Inc today announced that its abstract, Oral SM-88 plus MPS, an effective yet less toxic treatment option in second-line advanced pancreatic cancer? Final phase II/III study results, has been accepted for poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, January 20 – 22, 2022, in San Francisco, CA.

GRO Biosciences Inc. today announced the appointment of Bruce Beutel, PhD to its Board of Directors and its upcoming participation and activity during J.P. Morgan Health Care Week in January 2022.

Achilles Therapeutics plc today presented positive data at the ESMO Immuno-Oncology Congress 2021.

Sciwind Biosciences Co., Ltd. today announced the completion of patient enrollment in its Phase 2 clinical trial of XW003 in type 2 diabetes patients in China.

4D pharma Presents Microbiome Analyses from Phase II Clinical Trial of Blautix ® for IBS-C and IBS-D at Gastro 2021.

Sesen Bio today announced its anticipated regulatory path forward for Vicineum™ or the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) following its Clinical Type A meeting with the US Food and Drug Administration (FDA), which occurred on December 8, 2021 (Clinical Type A Meeting).